皮卡佐剂狂犬病疫苗的有效性

Effectiveness of Rabies Vaccine Using PICKCa Adjuvant

皮卡佐剂狂犬病疫苗已取得国家临床研究批件。在暴露后免疫中,即使未同时接种抗血清,皮卡佐剂狂犬病疫苗也具有良好的保护效果,明显优于无佐剂的市售疫苗。因此,皮卡佐剂狂犬病疫苗有可能发展为一种治疗性疫苗,在无法实施抗血清接种时,用于Ⅲ度暴露后咬伤患者的免疫。本文就有关该疫苗的有效性作一综述,包括皮卡佐剂狂犬病疫苗的非特异性免疫功能及在动物体内的体液免疫和细胞免疫应答。

The rabies vaccine using PICKCa adjuvant has been licensed for clinical study.The vaccine shows good protective effect which is superior to that of commercial adjuvant-free rabies vaccine in post-exposure immunization,even no antiserum was inoculated simultaneously.Thus the rabies vaccine using PICKCa adjuvant may be used as a candidate therapeutic vaccine for immunization to the patients with exposure of degree Ⅲ when inoculation with antiserum is unavailable.This paper reviews the effectiveness of the vaccine,including non-specific immune function as well as humoral and cellular immune responses in animals.